TY  - JOUR
AU  - Alhalabi, Obada T
AU  - Dao Trong, Philip
AU  - Kaes, Manuel
AU  - Jakobs, Martin
AU  - Kessler, Tobias
AU  - Oehler, Hannah
AU  - König, Laila
AU  - Eichkorn, Tanja
AU  - Sahm, Felix
AU  - Debus, Jürgen
AU  - von Deimling, Andreas
AU  - Wick, Wolfgang
AU  - Wick, Antje
AU  - Krieg, Sandro M
AU  - Unterberg, Andreas W
AU  - Jungk, Christine
TI  - Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk-benefit analysis.
JO  - Journal of neuro-oncology
VL  - 167
IS  - 2
SN  - 0167-594X
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - DKFZ-2024-00311
SP  - 245-255
PY  - 2024
N1  - 2024 Apr;167(2):245-255
AB  - Surgery for recurrent glioma provides cytoreduction and tissue for molecularly informed treatment. With mostly heavily pretreated patients involved, it is unclear whether the benefits of repeat surgery outweigh its potential risks.Patients receiving surgery for recurrent glioma WHO grade 2-4 with the goal of tissue sampling for targeted therapies were analyzed retrospectively. Complication rates (surgical, neurological) were compared to our institutional glioma surgery cohort. Tissue molecular diagnostic yield, targeted therapies and post-surgical survival rates were analyzed.Between 2017 and 2022, tumor board recommendation for targeted therapy through molecular diagnostics was made for 180 patients. Of these, 70 patients (38
KW  - Molecular diagnostics (Other)
KW  - Precision oncology (Other)
KW  - Recurrent glioma (Other)
KW  - Surgical complications (Other)
KW  - Targeted therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38334907
DO  - DOI:10.1007/s11060-024-04595-5
UR  - https://inrepo02.dkfz.de/record/287683
ER  -